![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via
toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study
|
|
|
EASL 2022 June 22-26 London
You S1, Delahaye J1, Ermler M1, Singh J1, Jordan W1, Ray A1, Galwey N2, Austin D3, Theodore D4, Paff M1
1GlaxoSmithKline, Collegeville, PA, USA; 2GlaxoSmithKline, Stevenage, Hertfordshire, UK; 3GlaxoSmithKline, Brentford, Middlesex, UK; 4GlaxoSmithKline, Research Triangle Park, NC, USA
EASL: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study - (06/26/22)
![0725221](../images/072522/072522-4/0725221.gif)
![0725222](../images/072522/072522-4/0725222.gif)
![0725223](../images/072522/072522-4/0725223.gif)
![0725224](../images/072522/072522-4/0725224.gif)
![0725225](../images/072522/072522-4/0725225.gif)
![0725226](../images/072522/072522-4/0725226.gif)
![0725227](../images/072522/072522-4/0725227.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|